Glaukos Posts $211M in Third-Quarter Sales
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (1.9× avg).
Summary
Glaukos reported third-quarter sales of $211 million, up 58% and up from $185.6 million in Q2 2026 — roughly a 14% sequential increase. Third-quarter net income was $2.0 million, or $0.03 diluted EPS, while non-GAAP net income was $28.5 million, or $0.47 EPS, and the company held cash of $339.8 million. The company now guides 2026 to $775–$785 million and 2027 to $1 billion. The top line is the headline number here. The stock has been volatile, dropping over 13% on October 8 after insider selling overshadowed positive pipeline news, so a clean revenue beat of the prior quarter's run rate matters for sentiment.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Glaukos Q3 2026 net income was $2.0 million ($0.03 diluted EPS) and non-GAAP net income $28.5 million ($0.47 EPS), with cash of $339.8 million.
At the time of this announcement, GKOS was trading at $181.43 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $73.16 to $191.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.